SEPN
Septerna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$36.75
−0.14%0
Insider buys (3m)
14
Insider sells (3m)
-$41.5M
Net value (3m)
+18.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | Sale | 3,333 | $38 |
| Sep 3, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | M-Exempt | 3,333 | $2.76 |
| Aug 14, 2026 | Third Rock Ventures V, L.P. · 10 percent owner | Sale | 147,059 | $50 |
| Aug 14, 2026 | RA CAPITAL MANAGEMENT, L.P. · director, 10 percent owner: | Sale | 746,500 | $43 |
| Aug 14, 2026 | Third Rock Ventures V, L.P. · 10 percent owner | Sale | 141 | $51 |
| Aug 13, 2026 | Bhatt Elizabeth · officer: President and COO | M-Exempt | 6,319 | $2.76 |
| Aug 13, 2026 | Bhatt Elizabeth · officer: President and COO | Sale | 25,000 | $44 |
| Aug 13, 2026 | Bhatt Elizabeth · officer: President and COO | M-Exempt | 18,681 | $6.81 |
| Aug 5, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | M-Exempt | 1,518 | $2.76 |
| Aug 5, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | Sale | 2,334 | $35 |
| Aug 5, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | Sale | 1,000 | $34 |
| Aug 5, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | M-Exempt | 1,816 | $2.76 |
| Jul 17, 2026 | Bhatt Elizabeth · officer: President and COO | Sale | 4,000 | $34 |
| Jul 17, 2026 | Bhatt Elizabeth · officer: President and COO | M-Exempt | 4,000 | $6.81 |
| Jul 2, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | Sale | 2,100 | $34 |
| Jul 2, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | Sale | 1,233 | $35 |
| Jul 2, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | M-Exempt | 3,333 | $2.76 |
| Jun 30, 2026 | Shaikhly Samira · officer: Chief People Officer | M-Exempt | 2,178 | $6.81 |
| Jun 30, 2026 | Simson Jake · director | A-Award | 15,000 | $37 |
| Jun 30, 2026 | Ezekowitz Alan · director | A-Award | 15,000 | $37 |
| Jun 30, 2026 | Gottesdiener Keith Michael · director | A-Award | 11,260 | $37 |
| Jun 30, 2026 | Tong Jeffrey K · director | A-Award | 15,000 | $37 |
| Jun 30, 2026 | Coulie Bernard · director | A-Award | 15,000 | $37 |
| Jun 30, 2026 | Sharp Shalini · director | A-Award | 15,000 | $37 |
| Jun 30, 2026 | Bassan Abraham · director | A-Award | 15,000 | $37 |
| Jun 30, 2026 | Shaikhly Samira · officer: Chief People Officer | Sale | 2,178 | $35 |
| Jun 30, 2026 | RA CAPITAL MANAGEMENT, L.P. · director, 10 percent owner: | A-Award | 15,000 | $37 |
| Jun 24, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | M-Exempt | 4,471 | $12 |
| Jun 24, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | Sale | 7,000 | $36 |
| Jun 24, 2026 | Long Daniel D. · officer: SVP, Drug Discovery | Sale | 8,000 | $35 |
Institutional positioning
13F filings over the trailing two quarters
New 78Increased 93Reduced 66Sold out 15
| Filer | Action | Shares | Filed |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 6,995,858 | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 6,995,858 | Aug 14, 2026 |
| TRV GP V, LLC | Unchanged | 6,215,591 | May 7, 2026 |
| TRV GP V, LLC | Unchanged | 6,215,591 | Aug 10, 2026 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | Increased | 4,433,058 | Aug 14, 2026 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | Reduced | 4,395,572 | May 15, 2026 |
| TRV GP VI, LLC | Unchanged | 4,211,659 | May 7, 2026 |
| TRV GP VI, LLC | Unchanged | 4,211,659 | Aug 10, 2026 |
| SAMSARA BIOCAPITAL, LLC | Unchanged | 3,149,128 | May 15, 2026 |
| Samsara BioCapital, LLC | Unchanged | 3,149,128 | Aug 14, 2026 |
| GOLDMAN SACHS GROUP INC | Increased | 3,062,766 | Aug 14, 2026 |
| GOLDMAN SACHS GROUP INC | Reduced | 2,906,427 | May 15, 2026 |
| GOLDMAN SACHS GROUP INC | Increased | 2,715,129 | Mar 25, 2026 |
| SIREN, L.L.C. | Unchanged | 2,000,000 | May 14, 2026 |
| BlackRock, Inc. | Increased | 1,932,088 | Aug 7, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 3, 2026